Related Experiment Video
Updated: Sep 2, 2025
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
Understanding COVID-19-associated coagulopathy
Edward M Conway1, Nigel Mackman2, Ronald Q Warren3
1Centre for Blood Research, Life Sciences Institute, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Insights
COVID-19-associated coagulopathy (CAC) involves complex interactions leading to blood clot formation. Understanding these mechanisms is crucial for developing diagnostics and treatments for this SARS-CoV-2 complication.
Area of Science:
- Pathology
- Immunology
- Vascular Biology
Background:
- COVID-19-associated coagulopathy (CAC) is a severe complication of SARS-CoV-2 infection.
- The precise cellular and molecular mechanisms underlying CAC remain incompletely understood.
- CAC involves intricate interplay between the immune system, coagulation, and endothelium, promoting thrombosis.
Purpose of the Study:
- To review and categorize the current understanding of CAC pathogenesis.
- To identify critical research gaps and pose key questions for future investigation.
- To discuss the utility of animal models for studying CAC.
Main Methods:
- This perspective synthesizes existing evidence on CAC.
- It categorizes pathological mechanisms into endothelial dysfunction, hyper-inflammation, and hypercoagulability.
- It highlights areas needing further research and discusses animal model suitability.
Main Results:
- CAC pathogenesis is multifactorial, involving vascular, immune, and coagulation systems.
- Key research gaps exist in understanding CAC at genomic, molecular, and cellular levels.
- Further research is needed to improve diagnostics and therapeutic strategies for CAC.
Conclusions:
- A comprehensive understanding of CAC mechanisms is essential for clinical management.
- Targeted research is required to address identified knowledge gaps.
- Developing effective diagnostics and therapeutics for CAC remains a priority.
Abstract:
COVID-19-associated coagulopathy (CAC) is a life-threatening complication of SARS-CoV-2 infection. However, the underlying cellular and molecular mechanisms driving this condition are unclear. Evidence supports the concept that CAC involves complex interactions between the innate immune response, the coagulation and fibrinolytic pathways, and the vascular endothelium, resulting in a procoagulant condition. Understanding of the pathogenesis of this condition at the genomic, molecular and cellular levels is needed in order to mitigate thrombosis formation in at-risk patients. In this Perspective, we categorize our current understanding of CAC into three main pathological mechanisms: first, vascular endothelial cell dysfunction; second, a hyper-inflammatory immune response; and last, hypercoagulability. Furthermore, we pose key questions and identify research gaps that need to be addressed to better understand CAC, facilitate improved diagnostics and aid in therapeutic development. Finally, we consider the suitability of different animal models to study CAC.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:05Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...